HDCT and Stem Cell Transplantation for Mantle Cell and Relapsed Low Grade Non-Hodgkin's Lymphoma

This study is currently recruiting participants.

Verified by Alberta Cancer Board, July 2006

Sponsored by:	Alberta Cancer Board
Information provided by:	Alberta Cancer Board
ClinicalTrials.gov Identifier:	NCT00144092

Purpose

Low grade lymphoma patients receive R-ICE reinduction therapy followed by allogeneic stem cell transplanation.

Condition	Intervention	Phase
Low Grade Lymphoma	Procedure: stem cell source	Phase II

MedlinePlus related topics: Cancer Lymphoma

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Non-Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study
Official Title:	High Dose Chemotherapy and Autologous or Allogeneic Blood Stem Cell Transplantation for Mantle Cell and Relapsed Low Grade Non-Hodgkin's Lymphoma

Further study details as provided by Alberta Cancer Board:

Primary Outcome Measures:

feasibility
mortality
overall survival
event free survival

Estimated Enrollment:	60
Study Start Date:	May 2001
Estimated Study Completion Date:	May 2005

Detailed Description:

Low grade lymphoma patients receive R-ICE reinduction therapy followed by allogeneic stem cell transplanation if they have an HLA matched sibling, or an autologous transplant if they do not.

Eligibility

Ages Eligible for Study:	18 Years to 65 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

indolent histology lymphomas after relapse 1 or 2 LVEF > 50% Creatinine < 150 umol/L bilirubin < 30 umol/L wbc >3.5X10^9/L platelets >100X10^9/L other medical condition as controlled

Exclusion Criteria:

pregnant lactating HIV positive CNS involvement by lymphoma other malignancy

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00144092

Contacts

Contact: Doug Stewart, MD

clinical_trials_tbcc@cancerboard.ab.ca

Locations

Canada, Alberta
Tom Baker Cancer Centre	Recruiting
Calgary, Alberta, Canada, T2N 4N2
Contact: Rachel Syme, PhD clinical_trials_tbcc@cancerboard.ab.ca

Sponsors and Collaborators

Alberta Cancer Board

Investigators

Principal Investigator:

Doug Stewart

Alberta Cancer Board - TBCC

More Information

Study ID Numbers:	147, 15841
Study First Received:	September 1, 2005
Last Updated:	July 12, 2006
ClinicalTrials.gov Identifier:	NCT00144092
Health Authority:	Canada: Health Canada

Keywords provided by Alberta Cancer Board:

autologous and allogeneic stem cell transplantation
low grade lymphoma
mantle cell

Study placed in the following topic categories:

Lymphatic Diseases
Immunoproliferative Disorders
Lymphoma, small cleaved-cell, diffuse

Lymphoproliferative Disorders
Lymphoma, Non-Hodgkin
Lymphoma

Additional relevant MeSH terms:

Neoplasms
Neoplasms by Histologic Type
Immune System Diseases

ClinicalTrials.gov processed this record on January 16, 2009